Immutep announces initiation of Phase II trial in soft tissue sarcoma

Immutep announces the initiation of an open-label Phase II trial evaluating eftilagimod alpha, a soluble LAG-3 protein and MHC Class II agonist, in combination with pembrolizumab and radiotherapy in up to 40 soft tissue sarcoma patients in the neoadjuvant setting. The investigator-initiated study will be primarily funded by the Maria Skodowska-Curie National Research Institute of Oncology with an approved grant from the Polish government awarded by the Polish Medical Research Agency program. Immutep will provide efti at no cost as well as technical support. Immutep CEO, Marc Voigt added: "Efti’s unique potential to help safely drive superior clinical efficacy for cancer patients, with and without the use of chemotherapy, is attracting increasing attention from industry and academia. We are delighted to see efti and pembrolizumab, which together have led to deep and durable responses in several difficult-to-treat advanced solid tumours, being combined with radiotherapy for the first time and hope this approach can make a difference for soft tissue sarcoma patients who have limited treatment options."